Supporting the glycolytic phenotype in more aggressive tumors with poor prognosis, higher expressions of lactate dehydrogenase B (LDHB) and lactate transporters (MCT1 and MCT4) [43,44] and the inhibition of lactate secretion into the microenvironment to suppress tumor growth have been reported [45]. Here, LDHB is linked to neoplasm.